This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, Y. Articles by Viscidi, R. P. Search for Related Content PubMed PubMed Citation Articles by Sun, Y. Articles by Viscidi, R. P.

Serum Antibodies to Human Papillomavirus 16 Proteins in Women from Brazil with Invasive Cervical Carcinoma¹

Department of Pediatrics, Stanley Division of Developmental Neurovirology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 [Y. S., B. C., R. P. V.]; Department of Preventive Medicine, Faculdade de Medicina, Universidade de Sao Paulo, 455 Sao Paulo-SP, CEP 01246, Brazil [J. E-N.]; Institut Catala d‘Oncologia, 08907, Barcelona Spain [F. X. B.]; Unit of Field and Intervention Studies, International Agency for Research on Cancer, Lyon 69372, France [N. M.]; Department of Pathology, Free University Hospital, Amsterdam 1081 HV, the Netherlands [J. M. M. W., C. J. L. M. M.]; and Department of Molecular Medicine and Immunology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205 [K. V. S.]

Serum samples from 194 cases and 217 controls participating in a case-control study of invasive cervical cancer in Brazil were examined for antibodies to human papillomavirus (HPV) 16 virus-like particles (VLPs) by ELISA. The prevalence of antibody in cases and controls was 47.4 versus 24.4% (P < 0.001). The prevalence was higher in women who had HPV-16 DNA in the genital tract (54.2%) than in those with other HPVs (36.8%) or no HPVs (44.8%), but the differences were not statistically significant. Among cases and controls, HPV-16 VLP antibodies were associated with a greater number of lifetime sexual partners (² for trend, P < 0.001). Among controls, age was inversely associated with HPV-16 VLP seroreactivity (² for trend, P = 0.019). The sera were previously tested for antibodies to HPV-16 E6 and E7 oncoproteins; there was no correlation between antibody titers to HPV-16 E6 or E7 and VLPs. The HPV-16 serological assays were compared as screening tests for invasive cervical cancer. The sensitivity and specificity estimates were 47.4 and 75.6% for HPV-16 VLP serology, 63.4 and 89.9% for either HPV-16 E6 or E7 serology, and 53.6 and 93.6% for high titers of either HPV-16 E6 or E7 or VLP antibodies. The utility of HPV-16 VLP ELISA as a screening test for invasive cervical cancer is limited by a high seroprevalence in women with probable prior exposure to HVP 16 but without disease.

This article has been cited by other articles:

				S. Dillon, T. Sasagawa, A. Crawford, J. Prestidge, M. K. Inder, J. Jerram, A. A. Mercer, and M. Hibma Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2 J. Gen. Virol., March 1, 2007; 88(3): 803 - 813. [Abstract] [Full Text] [PDF]

				J P A Baak, A-J Kruse, S J Robboy, E A M Janssen, B van Diermen, and I Skaland Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers J. Clin. Pathol., October 1, 2006; 59(10): 1017 - 1028. [Abstract] [Full Text] [PDF]

				S. S. Wang and A. Hildesheim Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 35 - 40. [Abstract] [Full Text] [PDF]

				M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882. [Abstract] [Full Text] [PDF]